Citius Oncology presents Phase 1 data for LYMPHIR in gynecologic cancers
Citius Oncology highlighted Phase 1 data for LYMPHIR combined with pembrolizumab showing 24% overall response rate and 20.5 months median progression-free survival in heavily pre-treated patients with recurrent or refractory gynecologic malignancies. The positive clinical signals in checkpoint inhibitor-resistant tumors support continued development of this immunomodulatory approach.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day